AbbVie's Humira, one of the best-selling drugs for years, loses patent protection in early 2023. The partnership between Mark Cuban's Cost Plus Drug Company and Coherus BioSciences to offer a lower-cost biosimilar, Yusimry, could eat into AbbVie's market share. However, a Guggenheim analyst recently highlighted the strength of AbbVie's non-Humira business, with several blockbuster drugs potentially offsetting the loss of Humira revenue.

Abbott Laboratories spun off AbbVie in 2013, and while the partnership between Mark Cuban's Cost Plus Drug Company and Coherus BioSciences may impact AbbVie's market share, the direct effects on Abbott Laboratories are less clear. Abbott's stock performance has been strong over the last ten years, and the company has diversified its business since spinning off AbbVie.

The partnership with Mark Cuban's Cost Plus Drug Company will allow Coherus BioSciences to offer Yusimry, a biosimilar of Humira, at a lower cost. This could lead to an increase in market share for Coherus in the biologic space, as more patients gain access to affordable biologics. The partnership is also part of Coherus' biosimilar strategy to leverage its excellence in manufacturing and supply chain management.